The EGFR mutation status cannot be determined for some patients because of their tumor tissue cannot be acquired, the testing method and equipment used maybe different, and quality control limitations and so on [5]; thus, timely effective treatment is not possible for those patients, and it is necessary to find efficient alternative indicators of EGFR mutation status. This evidence concerns the gene EGFR and neoplasm.